Top of this page
Skip navigation, go straight to the content

Strategic partnerships to further strengthen R&D

  • Posted by

    Our recent partnership agreements with Parexel and PRA, along with the access to Lectus Therapeutics’ technology say a lot about where we are headed.

    Let’s start with the two new partnerships. The rationale behind these moves is simple: together we want to further improve clinical development productivity and increase our scope for innovation.

    We want to be able to outsource operational clinical work in a way that delivers cost-effectiveness without compromising on quality.

    Parexel and PRA are truly worldwide companies with expertise in immunology and central nervous system (CNS) therapeutic areas, amongst others. This reflects our own areas of focus and expertise.

    At UCB we deeply believe that partnerships and collaboration bring benefits to all.

    Our new partners will help us with a broad range of new clinical studies ranging from early phase development to post-approval research, along with other training and regulatory support.

    Parexel is itself already a global player with a growing presence in Asia. Coming shortly after the announcement of our support for a new epilepsy centre in Beijing, I see this as an indication that Asia will be amongst our focuses in the years to come.

    On top of this, November also saw the company strike an agreement with Lectus Therapeutics – a drug discovery company – to get exclusive access to their technology for our research in CNS.

    This is good news for ‘UCB NewMedicines’ and adds to our existing strengths in this therapeutic area.

    All in all, it turned out to be an exciting and productive November...
  • Like